|
|
 | | | |
- close
- close
- close
- close
Genmab (CPH:GEN) |
Benzinga
May 29
Comment
Genmab A/S
and GlaxoSmithKline plc (NYSE: GSK) announced today that their
Phase III study of ARZERRA^(R) (ofatumumab) in combination with chlorambucil
versus chlorambucil alone in patients with previously untreated chronic
lymphocytic leukemia...
FierceBiotech
May 1
Comment
Eight months after Johnson & Johnson ($JNJ) committed to a $1.1 billion deal package to partner on Genmab's cancer antibody daratumumab, the FDA has blessed the Phase I/II program with its new "breakthrough" designation.
The drug--which...
FierceBiotech
Feb 15
Comment
Here's more evidence that the biotech industry is giddy about the FDA's new "breakthrough therapy" designation. On speculation that its multiple myeloma contender could get the coveted status, Danish biotech Genmab's shares jumped in trading today...
Wealth Daily
Sep 4
Comment
Genmab A/S will work with Janssen Biotech to develop an antibody for a cancer molecule...
FierceBiotech
Aug 30
Comment
Johnson & Johnson isn't known for doing a lot of deals. But when the deal team moves, they do it decisively. That was the case today as J&J ($JNJ) finalized a pact to in-license a promising antibody from Genmab, taking an $80 million equity stake...
FierceBiotech
Jul 13
Comment
Danish biotech Genmab has nabbed a deal with Johnson & Johnson's ($JNJ) Janssen Biotech to develop bispecific antibody drugs, taking a rather modest $3.5 million upfront fee but gaining the opportunity to reap billions of dollars in future...
Globe Newswire
Jun 4
Comment
ADVISORY, June 4, 2012 (GLOBE NEWSWIRE) -- What: Genmab A/S, an international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer, will visit the NASDAQ
Globe Newswire
Jun 4
Comment
COPENHAGEN, Denmark, June 4, 2012 (GLOBE NEWSWIRE) -- Company Announcement - Additional DuoBody™ technology collaboration - USD 2 million upfront payment to Genmab Genmab A/S (Copenhagen:GEN) announced today an agreement with Novartis to use its
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
